Supernus Pharmaceuticals Cost of Goods Sold 2011-2024 | SUPN
Supernus Pharmaceuticals cost of goods sold from 2011 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Supernus Pharmaceuticals Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$84 |
| 2022 |
$87 |
| 2021 |
$75 |
| 2020 |
$52 |
| 2019 |
$17 |
| 2018 |
$15 |
| 2017 |
$15 |
| 2016 |
$12 |
| 2015 |
$8 |
| 2014 |
$6 |
| 2013 |
$1 |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-09-30 |
$18 |
| 2024-06-30 |
$18 |
| 2024-03-31 |
$16 |
| 2023-12-31 |
$20 |
| 2023-09-30 |
$20 |
| 2023-06-30 |
$21 |
| 2023-03-31 |
$23 |
| 2022-12-31 |
$23 |
| 2022-09-30 |
$26 |
| 2022-06-30 |
$20 |
| 2022-03-31 |
$18 |
| 2021-12-31 |
$17 |
| 2021-09-30 |
$18 |
| 2021-06-30 |
$25 |
| 2021-03-31 |
$15 |
| 2020-12-31 |
$19 |
| 2020-09-30 |
$21 |
| 2020-06-30 |
$8 |
| 2020-03-31 |
$4 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$5 |
| 2019-06-30 |
$4 |
| 2019-03-31 |
$4 |
| 2018-12-31 |
$4 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$3 |
| 2017-12-31 |
$4 |
| 2017-09-30 |
$4 |
| 2017-06-30 |
$4 |
| 2017-03-31 |
$3 |
| 2016-12-31 |
$4 |
| 2016-09-30 |
$3 |
| 2016-06-30 |
$3 |
| 2016-03-31 |
$2 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$2 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$0 |
| 2013-12-31 |
$1 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
